Earnings summaries and quarterly performance for MetaVia.
Executive leadership at MetaVia.
Board of directors at MetaVia.
Research analysts covering MetaVia.
Recent press releases and 8-K filings for MTVA.
MetaVia Prices $8.1 Million Underwritten Public Offering
MTVA
- MetaVia Inc. announced the pricing of its underwritten public offering for gross proceeds of approximately $8.1 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants.
- The offering includes 2,613,544 shares of common stock (or common stock equivalents), 3,920,316 Series C Warrants, and 3,920,316 Series D Warrants.
- These securities were priced at a combined public offering price of $3.10 per share of common stock and accompanying Series C and Series D Warrants.
- The Series C Warrants are immediately exercisable with an exercise price of $3.10 and expire on the five-year anniversary of the initial issuance date, while the Series D Warrants are immediately exercisable with an exercise price of $3.10 and expire on the two-year anniversary of the initial issuance date.
- MetaVia intends to use the net proceeds from the offering for working capital and general corporate purposes, including the clinical development of DA-1726 for the treatment of obesity.
Jan 16, 2026, 9:05 PM
MetaVia Closes $9.3 Million Underwritten Public Offering
MTVA
New Projects/Investments
- MetaVia Inc. closed its underwritten public offering for approximately $9.3 million in gross proceeds, including the full exercise of the underwriter's over-allotment option.
- The offering comprised 3,005,574 shares of common stock (or equivalents), 4,508,361 Series C Warrants, and 4,508,361 Series D Warrants, with a combined public offering price of $3.10 per share and accompanying warrants.
- If fully exercised for cash, the warrants could yield up to approximately $28.0 million in future gross proceeds.
- MetaVia intends to use the net proceeds for working capital and general corporate purposes, including the clinical development of DA-1726 for the treatment of obesity.
Jan 16, 2026, 9:01 PM
MetaVia prices underwritten public offering
MTVA
- MetaVia Inc. priced an underwritten public offering to raise approximately $8.1 million in gross proceeds.
- The offering consists of 2,613,544 shares of common stock (or common stock equivalents), 3,920,316 Series C Warrants, and 3,920,316 Series D Warrants at a combined public offering price of $3.10 per share.
- The Series C and D Warrants are immediately exercisable at $3.10, and their full exercise could generate up to approximately an additional $24.0 million in future gross proceeds.
- Net proceeds from the offering are intended for working capital and general corporate purposes, including the clinical development of DA-1726 for obesity.
- The offering is expected to close on or about January 16, 2026.
Jan 15, 2026, 2:32 PM
MetaVia Reports Positive Phase 1 Clinical Trial Results for DA-1726
MTVA
New Projects/Investments
- MetaVia Inc. announced positive statistically significant results from the 8-week non-titrated 48 mg multiple ascending dose cohort of its Phase 1 clinical trial of DA-1726 for the treatment of obesity, as of January 5, 2026.
- Key outcomes by Day 54 included a 9.1% average weight reduction (21.2 lbs), a statistically significant 9.8 cm reduction in waist circumference, a 12.3 mg/dL reduction in fasted glucose, and a 23.7% reduction in liver stiffness.
- The trial demonstrated a favorable safety and tolerability profile with no treatment-related discontinuations.
- MetaVia plans further 16-week titration studies for DA-1726, with results anticipated in the fourth quarter of 2026.
Jan 5, 2026, 1:32 PM
MetaVia Reports Positive Phase 1 Clinical Trial Results for DA-1726
MTVA
New Projects/Investments
- MetaVia Inc. announced positive statistically significant results from the 8-week non-titrated 48 mg multiple ascending dose cohort of its Phase 1 clinical trial for DA-1726, a novel dual oxyntomodulin (OXM) analog agonist for the treatment of obesity.
- Patients treated with DA-1726 achieved a robust average weight loss of 9.1% (21.2 lbs) and a statistically significant 9.8 cm (3.8 inch) reduction in waist circumference by Day 54.
- The trial demonstrated strong metabolic improvements, including a 12.3 mg/dL reduction in fasted glucose and a 23.7% reduction in liver stiffness (VCTE) by Day 54.
- DA-1726 exhibited a favorable safety and tolerability profile, with no treatment-related discontinuations and gastrointestinal events that were mild to moderate in severity.
- MetaVia plans to conduct further 16-week titration studies for DA-1726, with results expected in the fourth quarter of 2026.
Jan 5, 2026, 1:30 PM
MetaVia Presents Positive Phase 2a Data for Vanoglipel in MASH Patients
MTVA
New Projects/Investments
- MetaVia Inc. announced positive Phase 2a clinical trial results for vanoglipel (DA-1241), a GPR119 agonist, as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH).
- Following 16 weeks of treatment, vanoglipel demonstrated clinically meaningful reductions in HbA1c, with mean decreases of –0.54%p for monotherapy and –0.66%p for combination therapy.
- The drug also showed improvements in liver inflammation, fibrosis, and steatosis, including significant decreases in plasma ALT levels and favorable changes in plasma lipidomic profiles.
- Vanoglipel was well tolerated across all treatment groups, with no treatment-emergent adverse events leading to discontinuation, except for one in the placebo group.
Nov 7, 2025, 1:31 PM
MetaVia Reports Q3 2025 Financial Snapshot and Positive Clinical Trial Updates
MTVA
New Projects/Investments
- MetaVia reported a cash balance of $14.3 million and no debt as of September 30, 2025.
- The company's lead obesity therapeutic, DA-1726, demonstrated a mean weight loss of -4.3% (maximum -6.3%) at the 32 mg dose by Day 26 in its Phase 1 MAD study, with no treatment-related discontinuations due to mild GI related events.
- DA-1726 also showed a mean reduction in fasted glucose of -5.3 mg/dL and a mean waist circumference reduction of -4 cm at the 32 mg dose by Day 26 and Day 33, respectively.
- Vanoglipel (DA-1241) met its primary endpoint in the Phase 2a study for MASH, showing direct hepatic effects and significant reductions in HbA1C compared to placebo, with the company actively seeking a combination/licensing partner.
- Key near-term milestones include additional Phase 1 SAD/MAD data for DA-1726 in Q4 2025, initiation of Phase 2a for DA-1726 in Q2 2026, and an FDA meeting for Vanoglipel in H1 2026.
Nov 6, 2025, 9:31 PM
MetaVia Reports Third Quarter 2025 Financial Results and Provides Clinical Updates
MTVA
Earnings
New Projects/Investments
Guidance Update
- MetaVia Inc. reported a net loss of $3.4 million, or $0.14 per basic and diluted share, for the third quarter ended September 30, 2025.
- The company ended the third quarter with $14.3 million in cash, which is anticipated to fund operations into 2026.
- In clinical development, MetaVia dosed the first patient in the 8-week 48 mg MAD cohort of its Phase 1 trial for DA-1726 (obesity), with top-line data expected by year-end 2025.
- For vanoglipel (MASH), 16-week Phase 2a results showed meaningful reductions in liver fat, inflammation, and fibrosis, and an end-of-Phase 2 meeting with the FDA is planned for the first half of 2026.
Nov 6, 2025, 1:31 PM
MetaVia to Present Positive Phase 1 and Pre-Clinical Data for DA-1726 at ObesityWeek 2025
MTVA
New Projects/Investments
- MetaVia (MTVA) announced it will present new Phase 1 and pre-clinical data for its novel dual agonist, DA-1726, at ObesityWeek® 2025, highlighting its potential for obesity treatment.
- The Phase 1 data demonstrated favorable safety and tolerability, a pharmacokinetic profile supporting once-weekly dosing with a mean half-life of approximately 80 hours, and meaningful reductions in body weight and waist circumference.
- At the highest tested dose of 32 mg, participants achieved up to a 6.3% body-weight reduction from baseline (average 4.3% at Day 26) and waist circumference decreased by as much as 3.9 inches.
- Pre-clinical data showed DA-1726 achieved comparable weight loss to pemvidutide with superior lipid-lowering efficacy and produced greater weight loss than tirzepatide despite similar food intake.
- The Phase 1 study has been extended to evaluate a 48 mg dose for 8 weeks, with results expected later in 2025.
Nov 4, 2025, 9:01 PM
MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek 2025
MTVA
New Projects/Investments
- MetaVia Inc. announced that two abstracts highlighting data on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist, have been accepted for poster presentations at ObesityWeek® 2025, taking place November 4-7, 2025.
- DA-1726 is being developed for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH).
- In a Phase 1 multiple ascending dose (MAD) trial for obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction.
- Pre-clinical mouse models showed that DA-1726 improved weight loss compared to semaglutide (Wegovy®) and cotadutide, and elicited similar weight reduction to tirzepatide (Zepbound®) and survodutide while preserving lean body mass and demonstrating improved lipid-lowering effects compared to survodutide.
Oct 20, 2025, 12:31 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more